Announced Sat, 11 Oct · 21:22 IST

Statement of Deviation & Variation

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+2.6%1-day move

₹4.16

prior close

₹4.16

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+4.6+4.6+2.9+2.6+2.2+3.1+3.6+2.9+1.9-11.5-6.0-34.6-35.3

Up moveDown movePending

AI summary

Transgene Biotek has informed the Bombay Stock Exchange that the Statement of Deviation & Variation under SEBI's Regulation 32(1) is not applicable to the company for the quarter ended 30 September 2025. This is because the company did not raise any money through a public issue, rights issue, preferential issue, or Qualified Institutions Placement (QIP) during the quarter. The filing is a routine compliance confirmation, not a new fundraising event.

Likely market impact

No impact on shareholders or the stock price. This is a standard regulatory clarification confirming that no fresh capital was raised, so there is nothing to report on the use of issue proceeds.